[Patient follow-up after botulinum toxin intradetrusor injection. Proposal for management in neurogenic patients].
Injections of botulinum toxin into the detrusor is a major evolution for treatment of neurogenic bladder. They are now considered as a treatment of choice, safe and efficient, in refractory neurogenic overactivity in catheterized patient. To date, there are no consensual practical guidelines for the follow-up of patients having been treated by intradetrusor botulinum toxin, whatever the indication of the treatment, functional, that is, for improving continence and overactive bladder syndrome or organic, that is, for treatment of high-detrusor pressure and their deleterious impact of urinary tract. This lack of guidelines leads to heterogeneity of treatment management and limit the definition of optimal modalities of intradetrusor botulinum toxin treatment in neurogenic patients. The aim of your work, prepared jointly with the International Francophone Neuro-Urological expert study group (GENULF), aimed at putting forward well-informed specific recommendations for the follow-up of patients having been treated by intradetrusor botulinum toxin for functional or organic indication of neurogenic detrusor overactivity.
Service de médecine physique et de réadaptation, CHU Pellegrin, 33076 Bordeaux cedex, France. marianne.de-seze@chu-bordeaux.fr
M
M
de Sèze
A
A
Ruffion
F
F
Haab
E
E
Chartier-Kastler
P
P
Denys
X
X
Game
G
G
Karsenty
J
J
Kerdraon
B
B
Perrouin-Verbe
C
C
Saussine
J-M
JM
Soler
G
G
Amarenco
D019274:Botulinum Toxins, Type A / Q000627:therapeutic use*; D006801:Humans; D007273:Injections, Intramuscular; D009465:Neuromuscular Agents / Q000627:therapeutic use*; D001750:Urinary Bladder, Neurogenic / Q000188:drug therapy*; D014549:Urinary Incontinence / Q000188:drug therapy
D009465:Neuromuscular Agents; D019274:Botulinum Toxins, Type A